Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Change in Receivables of $8.1 million for Q1 2026, up 1280.49% year-over-year from $587470.5 in Q1 2025, and up 231.34% quarter-over-quarter from -$6.2 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 5 years of Change in Receivables data on file, last reported at $8.1 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at $8.1 million, up 1280.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.4 million (up 422.91% YoY), and the FY2025 annual result was $7.6 million, up 107.68% from the prior year.
- Change in Receivables improved to $8.1 million in Q1 2026 per RYTM's latest filing, from -$6.2 million in the prior quarter.
- Over five years, Change in Receivables peaked at $8.1 million in Q1 2026 and troughed at -$6.2 million in Q4 2025.
- A 5-year average of $2.1 million and a median of $1.7 million in 2024 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables slumped 677.71% in 2025, then surged 1280.49% in 2026.
- A 5-year view of Change in Receivables shows it stood at $2.9 million in 2022, then plunged by 88.74% to $326000.0 in 2023, then tumbled by 343.56% to -$794000.0 in 2024, then tumbled by 677.71% to -$6.2 million in 2025, then jumped by 231.34% to $8.1 million in 2026.
- Business Quant data shows RYTM's Change in Receivables at $8.1 million in Q1 2026, -$6.2 million in Q4 2025, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | 8.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.11 Mn |
| Mar 31, 2026 | 8.11 Mn |
| Dec 31, 2025 | -6.18 Mn |
| Dec 31, 2025 | -6.18 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 7.83 Mn |
| Jun 30, 2025 | 7.83 Mn |
| Mar 31, 2025 | -687,000.00 |
| Mar 31, 2025 | -687,000.00 |
| Dec 31, 2024 | -794,000.00 |
| Dec 31, 2024 | -794,000.00 |
| Sep 30, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | -172,000.00 |
| Mar 31, 2024 | -172,000.00 |
| Dec 31, 2023 | 326,000.00 |
| Dec 31, 2023 | 326,000.00 |